Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070525 · ClinicalTrials.gov registry record · Phase 2
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
A Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00070525: Completed Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma, sponsored by National Cancer Institute (NCI).
NCT00070525 is a Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants, above the 28-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (221% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070525, a Phase 2 study of Recurrent Childhood Medulloblastoma and Childhood High-grade Cerebral Astrocytoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Primary Outcome
Estimated ultimately as a simple binomial proportion. Estimated actuarially, using the product-limit (PL) estimate.
Conditions Studied
Interventions
- DRUG tipifarnib
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-11 |
| Phase | Phase 2 |
What the finished NCT00070525 record still lists
NCT00070525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 28-participant average among 3 other Recurrent Childhood Medulloblastoma trials with a reported enrollment target (221% higher).
The record links to 8 conditions, with Recurrent Childhood Medulloblastoma appearing as the primary indexed condition, and to 1 intervention - of which tipifarnib is the first listed.
NCT00070525 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00070525 about?
NCT00070525 is a clinical study titled "Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma". This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their grow...
What is the current status of trial NCT00070525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-11.
What conditions does trial NCT00070525 study?
This clinical trial studies the following conditions: Recurrent Childhood Medulloblastoma, Childhood High-grade Cerebral Astrocytoma, Recurrent Childhood Brain Stem Glioma, Childhood Oligodendroglioma, Recurrent Childhood Cerebellar Astrocytoma.
What interventions are being tested in trial NCT00070525?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00070525?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00070525 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Medulloblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
COMPLETED · Phase 2
-
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia